EGFR and neoplasm: Wu et al. conducted a phase II clinical trial, investigating the effects of capmatinib (400 mg twice a day) associated with gefitinib (250 mg once a day) in patients with activating MET mutations who had a background of tumor progression despite being administered anti-EGFR treatment.